| Source | Code | Name | Case count | Share of cases (%) |
|---|---|---|---|---|
| REIMB | REIMB_KELA(319)_ICD10(L40) | Adalimumab, brodalumab, certolizumab pegol, etanercept, guselkumab, infliximab, ixekizumab, risankizumab, sekukinumab and ustekinumab (skin psoriasis), Psoriasis | 472 | |
| REIMB | REIMB_KELA(319)_ICD10(L400) | Adalimumab, brodalumab, certolizumab pegol, etanercept, guselkumab, infliximab, ixekizumab, risankizumab, sekukinumab and ustekinumab (skin psoriasis), Psoriasis vulgaris | 409 | |
| REIMB | REIMB_KELA(134)_ICD10(L400) | General erythroderma, Psoriasis vulgaris | 194 | |
| REIMB | REIMB_KELA(319)_ICD10(L405) | Adalimumab, brodalumab, certolizumab pegol, etanercept, guselkumab, infliximab, ixekizumab, risankizumab, sekukinumab and ustekinumab (skin psoriasis), Arthropathic psoriasis (M07.0-M07.3*, M09.0*) | 127 | |
| REIMB | REIMB_KELA(377)_ICD10(L40) | Apremilast and dimethyl fumarate (psoriasis), Psoriasis | 109 | |
| REIMB | REIMB_KELA(377)_ICD10(L405) | Apremilast and dimethyl fumarate (psoriasis), Arthropathic psoriasis (M07.0-M07.3*, M09.0*) | 76 | |
| REIMB | REIMB_KELA(377)_ICD10(L400) | Apremilast and dimethyl fumarate (psoriasis), Psoriasis vulgaris | 56 | |
| REIMB | REIMB_KELA(134)_ICD9(NA) | General erythroderma, Name not found | 52 | |
| REIMB | REIMB_KELA(134)_ICD10(L26) | General erythroderma, Exfoliative dermatitis | 31 | |
| REIMB | REIMB_KELA(134)_ICD8(NA) | General erythroderma, Name not found | 15 | |
| REIMB | REIMB_KELA(319)_ICD10(L408) | Adalimumab, brodalumab, certolizumab pegol, etanercept, guselkumab, infliximab, ixekizumab, risankizumab, sekukinumab and ustekinumab (skin psoriasis), Other psoriasis | 14 | |
| REIMB | REIMB_KELA(134)_ICD9(6961A) | General erythroderma, Psoriasis and similar disorders, Other psoriasis | 12 | |
| REIMB | REIMB_KELA(134)_ICD10(L20) | General erythroderma, Atopic dermatitis | 7 | |
| REIMB | REIMB_KELA(134)_ICD10(NA) | General erythroderma, Name not found | 6 | |
| REIMB | REIMB_KELA(319)_ICD10(L402) | Adalimumab, brodalumab, certolizumab pegol, etanercept, guselkumab, infliximab, ixekizumab, risankizumab, sekukinumab and ustekinumab (skin psoriasis), Acrodermatitis continua | 6 |